{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T17:12:08Z","timestamp":1743095528037,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":153,"publisher":"Springer New York","isbn-type":[{"type":"print","value":"9781461485193"},{"type":"electronic","value":"9781461485209"}],"license":[{"start":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T00:00:00Z","timestamp":1378252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T00:00:00Z","timestamp":1378252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014]]},"DOI":"10.1007\/978-1-4614-8520-9_13","type":"book-chapter","created":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T21:01:25Z","timestamp":1380142885000},"page":"141-158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biological Therapy for Multiple Myeloma"],"prefix":"10.1007","author":[{"given":"Camilo","family":"Ayala-Breton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kah-Whye","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,9,4]]},"reference":[{"key":"13_CR00131","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11882-012-0327-7","volume":"13","author":"S Baskar","year":"2012","unstructured":"Baskar S, Muthusamy N. Antibody-based therapeutics for the treatment of human B cell malignancies. Curr Allergy Asthma Rep. 2012;13:33\u201343.","journal-title":"Curr Allergy Asthma Rep"},{"key":"13_CR00132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-921-1_1","volume":"899","author":"DS Dimitrov","year":"2012","unstructured":"Dimitrov DS. Therapeutic proteins. Methods Mol Biol. 2012;899:1\u201326.","journal-title":"Methods Mol Biol"},{"issue":"10","key":"13_CR00133","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2174\/138945006778559139","volume":"7","author":"RJ Kreitman","year":"2006","unstructured":"Kreitman RJ, Pastan I. Immunotoxins in the treatment of hematologic malignancies. Curr Drug Targets. 2006;7(10):1301\u201311.","journal-title":"Curr Drug Targets"},{"issue":"21","key":"13_CR00134","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1056\/NEJMct1114348","volume":"366","author":"DG Maloney","year":"2012","unstructured":"Maloney DG. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med. 2012;366(21): 2008\u201316.","journal-title":"N Engl J Med"},{"issue":"2","key":"13_CR00135","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s11864-012-0186-4","volume":"13","author":"D Jelovac","year":"2012","unstructured":"Jelovac D, Wolff AC. The adjuvant treatment of HER2-positive breast cancer. Curr Treat Options Oncol. 2012;13(2):230\u20139.","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"13_CR00136","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.ctrv.2011.11.002","volume":"38","author":"CL Vale","year":"2012","unstructured":"Vale CL, et al. Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis. Cancer Treat Rev. 2012;38(6):618\u201325.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"13_CR00137","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff ME, et al. Depletion of B-cells in-vivo by a chimeric mouse-human monoclonal-antibody to Cd20. Blood. 1994;83(2):435\u201345.","journal-title":"Blood"},{"issue":"1","key":"13_CR00138","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/00002371-200201000-00008","volume":"25","author":"SP Treon","year":"2002","unstructured":"Treon SP, et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother. 2002;25(1):72\u201381.","journal-title":"J Immunother"},{"issue":"1","key":"13_CR00139","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/sj.leu.2404972","volume":"22","author":"PT Greipp","year":"2008","unstructured":"Greipp PT, et al. Reply to \u2018Rituximab in CD20 positive multiple myeloma\u2019 by P Moreau et al. Leukemia. 2008;22(1):214\u20135.","journal-title":"Leukemia"},{"issue":"2","key":"13_CR001310","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1365-2141.2008.07024.x","volume":"141","author":"P Kapoor","year":"2008","unstructured":"Kapoor P, et al. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol. 2008;141(2):135\u201348.","journal-title":"Br J Haematol"},{"issue":"4","key":"13_CR001311","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ccr.2006.08.025","volume":"10","author":"J Yang","year":"2006","unstructured":"Yang J, et al. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell. 2006;10(4):295\u2013307.","journal-title":"Cancer Cell"},{"issue":"3","key":"13_CR001312","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1158\/1078-0432.CCR-08-1823","volume":"15","author":"J Yang","year":"2009","unstructured":"Yang J, et al. Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. Clin Cancer Res. 2009;15(3):951\u20139.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"13_CR001313","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/0167-5699(94)90148-1","volume":"15","author":"F Malavasi","year":"1994","unstructured":"Malavasi F, et al. Human CD38: a glycoprotein in search of a function. Immunol Today. 1994;15(3): 95\u20137.","journal-title":"Immunol Today"},{"issue":"4","key":"13_CR001314","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1309\/74R4TB90BUWH27JX","volume":"121","author":"P Lin","year":"2004","unstructured":"Lin P, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol. 2004;121(4):482\u20138.","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"13_CR001315","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840\u20138.","journal-title":"J Immunol"},{"issue":"13","key":"13_CR001316","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1158\/0008-5472.CAN-04-4125","volume":"65","author":"YT Tai","year":"2005","unstructured":"Tai YT, et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005;65(13):5898\u2013906.","journal-title":"Cancer Res"},{"issue":"1","key":"13_CR001317","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1365-2141.2012.09251.x","volume":"159","author":"W Bensinger","year":"2012","unstructured":"Bensinger W, et al. A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol. 2012;159(1):58\u201366.","journal-title":"Br J Haematol"},{"issue":"5","key":"13_CR001318","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3324\/haematol.2009.008003","volume":"95","author":"M Hussein","year":"2010","unstructured":"Hussein M, et al. A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica. 2010;95(5):845\u20138.","journal-title":"Haematologica"},{"issue":"Pt 2","key":"13_CR001319","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1042\/bj3040525","volume":"304","author":"WJ Mawby","year":"1994","unstructured":"Mawby WJ, et al. Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin-associated protein (IAP) and the ovarian tumour marker OA3. Biochem J. 1994;304(Pt 2):525\u201330.","journal-title":"Biochem J"},{"issue":"5","key":"13_CR001320","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood.V99.5.1745","volume":"99","author":"F Zhan","year":"2002","unstructured":"Zhan F, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99(5):1745\u201357.","journal-title":"Blood"},{"issue":"12","key":"13_CR001321","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1038\/leu.2012.141","volume":"26","author":"D Kim","year":"2012","unstructured":"Kim D, et al. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia. 2012;26(12):2538\u201345.","journal-title":"Leukemia"},{"issue":"8","key":"13_CR001322","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood.V79.8.2068.2068","volume":"79","author":"EJ Ahsmann","year":"1992","unstructured":"Ahsmann EJ, et al. Lymphocyte function-associated antigen-1 expression on plasma cells correlates with tumor growth in multiple myeloma. Blood. 1992;79(8):2068\u201375.","journal-title":"Blood"},{"issue":"6","key":"13_CR001323","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1089\/hyb.1993.12.661","volume":"12","author":"YW Huang","year":"1993","unstructured":"Huang YW, Burrows FJ, Vitetta ES. Cytotoxicity of a novel anti-ICAM-1 immunotoxin on human myeloma cell lines. Hybridoma. 1993;12(6):661\u201375.","journal-title":"Hybridoma"},{"issue":"6","key":"13_CR001324","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00002371-200411000-00001","volume":"27","author":"JE Smallshaw","year":"2004","unstructured":"Smallshaw JE, et al. The generation and anti-myeloma activity of a chimeric anti-CD54 antibody, cUV3. J Immunother. 2004;27(6):419\u201324.","journal-title":"J Immunother"},{"issue":"3","key":"13_CR001325","first-page":"610","volume":"55","author":"YW Huang","year":"1995","unstructured":"Huang YW, Richardson JA, Vitetta ES. Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells. Cancer Res. 1995;55(3): 610\u20136.","journal-title":"Cancer Res"},{"issue":"2","key":"13_CR001326","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/10428190701760532","volume":"49","author":"M Kraj","year":"2008","unstructured":"Kraj M, et al. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma. Leuk Lymphoma. 2008;49(2):298\u2013305.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"13_CR001327","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/blood.V81.10.2658.2658","volume":"81","author":"H Harada","year":"1993","unstructured":"Harada H, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993;81(10):2658\u201363.","journal-title":"Blood"},{"issue":"13","key":"13_CR001328","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1158\/0008-5472.CAN-04-0142","volume":"64","author":"P Tassone","year":"2004","unstructured":"Tassone P, et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2\u2032-deacetyl-N2\u2032-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 2004;64(13):4629\u201336.","journal-title":"Cancer Res"},{"issue":"19","key":"13_CR001329","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-04-0182","volume":"10","author":"JD Burton","year":"2004","unstructured":"Burton JD, et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res. 2004;10(19):6606\u201311.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"13_CR001330","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood-2004-03-0890","volume":"104","author":"R Stein","year":"2004","unstructured":"Stein R, et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood. 2004;104(12):3705\u201311.","journal-title":"Blood"},{"issue":"14","key":"13_CR001331","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1158\/1078-0432.CCR-05-0204","volume":"11","author":"P Sapra","year":"2005","unstructured":"Sapra P, et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res. 2005;11(14):5257\u201364.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"13_CR001332","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1091\/mbc.1.1.27","volume":"1","author":"RD Sanderson","year":"1989","unstructured":"Sanderson RD, Lalor P, Bernfield M. B lymphocytes express and lose syndecan at specific stages of differentiation. Cell Regul. 1989;1(1):27\u201335.","journal-title":"Cell Regul"},{"issue":"12","key":"13_CR001333","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1158\/1078-0432.CCR-08-2867","volume":"15","author":"H Ikeda","year":"2009","unstructured":"Ikeda H, et al. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009;15(12):4028\u201337.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"13_CR001334","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","volume":"14","author":"ED Hsi","year":"2008","unstructured":"Hsi ED, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res. 2008;14(9):2775\u201384.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"13_CR001335","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","volume":"112","author":"YT Tai","year":"2008","unstructured":"Tai YT, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008;112(4): 1329\u201337.","journal-title":"Blood"},{"issue":"9","key":"13_CR001336","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1158\/1535-7163.MCT-09-0483","volume":"8","author":"F van Rhee","year":"2009","unstructured":"van Rhee F, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther. 2009;8(9):2616\u201324.","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"13_CR001337","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2011.40.4061","volume":"30","author":"DM Benson Jr","year":"2012","unstructured":"Benson Jr DM, Byrd JC. CS1-directed monoclonal antibody therapy for multiple myeloma. J Clin Oncol. 2012;30(16):2013\u20135.","journal-title":"J Clin Oncol"},{"issue":"4","key":"13_CR001338","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V85.4.863.bloodjournal854863","volume":"85","author":"B Klein","year":"1995","unstructured":"Klein B, et al. Interleukin-6 in human multiple myeloma. Blood. 1995;85(4):863\u201372.","journal-title":"Blood"},{"issue":"23","key":"13_CR001339","doi-asserted-by":"crossref","first-page":"7144","DOI":"10.1158\/1078-0432.CCR-09-1483","volume":"15","author":"M Fulciniti","year":"2009","unstructured":"Fulciniti M, et al. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009;15(23):7144\u201352.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"13_CR001340","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1046\/j.1365-2141.1998.00835.x","volume":"102","author":"HC van Zaanen","year":"1998","unstructured":"van Zaanen HC, et al. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol. 1998;102(3):783\u201390.","journal-title":"Br J Haematol"},{"issue":"16","key":"13_CR001341","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2011.37.2649","volume":"30","author":"S Lonial","year":"2012","unstructured":"Lonial S, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30(16):1953\u20139.","journal-title":"J Clin Oncol"},{"key":"13_CR001342","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/ejh.12107","volume":"90","author":"A Allegra","year":"2013","unstructured":"Allegra A, et al. Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. Eur J Haematol. 2013;90:441\u201368.","journal-title":"Eur J Haematol"},{"issue":"16","key":"13_CR001343","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2011.37.7069","volume":"30","author":"AJ Jakubowiak","year":"2012","unstructured":"Jakubowiak AJ, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed\/refractory multiple myeloma. J Clin Oncol. 2012;30(16):1960\u20135.","journal-title":"J Clin Oncol"},{"issue":"3","key":"13_CR001344","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1046\/j.1365-2141.2000.02093.x","volume":"109","author":"P Moreau","year":"2000","unstructured":"Moreau P, et al. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol. 2000;109(3):661\u20134.","journal-title":"Br J Haematol"},{"issue":"37","key":"13_CR001345","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.1016\/j.vaccine.2010.06.088","volume":"28","author":"F-L Zhou","year":"2010","unstructured":"Zhou F-L, et al. Peptide-based immunotherapy for multiple myeloma: current approaches. Vaccine. 2010;28(37):5939\u201346.","journal-title":"Vaccine"},{"key":"13_CR001346","first-page":"820394","volume":"2012","author":"L Zhang","year":"2012","unstructured":"Zhang L, et al. Immunogenic targets for specific immunotherapy in multiple myeloma. Clin Dev Immunol. 2012;2012:820394.","journal-title":"Clin Dev Immunol"},{"issue":"9","key":"13_CR001347","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.leukres.2011.03.032","volume":"35","author":"TN Nguyen-Pham","year":"2011","unstructured":"Nguyen-Pham TN, et al. Induction of myeloma-specific cytotoxic T lymphocytes responses by natural killer cells stimulated-dendritic cells in patients with multiple myeloma. Leuk Res. 2011;35(9):1241\u20137.","journal-title":"Leuk Res"},{"issue":"5","key":"13_CR001348","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1073\/pnas.94.5.1914","volume":"94","author":"YT Chen","year":"1997","unstructured":"Chen YT, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997;94(5):1914\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"13_CR001349","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-230X(06)95001-5","volume":"95","author":"S Gnjatic","year":"2006","unstructured":"Gnjatic S, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006;95: 1\u201330.","journal-title":"Adv Cancer Res"},{"issue":"10","key":"13_CR001350","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1080\/10428190600742292","volume":"47","author":"S Szmania","year":"2006","unstructured":"Szmania S, Tricot G, van Rhee F. NY-ESO-1 immunotherapy for multiple myeloma. Leuk Lymphoma. 2006;47(10):2037\u201348.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"13_CR001351","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1182\/blood-2004-09-3707","volume":"105","author":"F van Rhee","year":"2005","unstructured":"van Rhee F, et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005;105(10):3939\u201344.","journal-title":"Blood"},{"issue":"2","key":"13_CR001352","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.coi.2008.04.009","volume":"20","author":"Y Oka","year":"2008","unstructured":"Oka Y, et al. WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol. 2008;20(2):211\u201320.","journal-title":"Curr Opin Immunol"},{"issue":"21","key":"13_CR001353","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1158\/1078-0432.CCR-04-0825","volume":"10","author":"T Azuma","year":"2004","unstructured":"Azuma T, et al. Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes. Clin Cancer Res. 2004;10(21):7402\u201312.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"13_CR001354","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/BF02983998","volume":"86","author":"A Tsuboi","year":"2007","unstructured":"Tsuboi A, et al. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol. 2007;86(5):414\u20137.","journal-title":"Int J Hematol"},{"issue":"5","key":"13_CR001355","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2004-01-0366","volume":"105","author":"C Choi","year":"2005","unstructured":"Choi C, et al. Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma. Blood. 2005;105(5): 2132\u20134.","journal-title":"Blood"},{"issue":"18","key":"13_CR001356","first-page":"6846","volume":"61","author":"P Brossart","year":"2001","unstructured":"Brossart P, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 2001;61(18):6846\u201350.","journal-title":"Cancer Res"},{"issue":"1","key":"13_CR001357","first-page":"95","volume":"29","author":"K Giannopoulos","year":"2006","unstructured":"Giannopoulos K, et al. Expression of RHAMM\/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia. Int J Oncol. 2006;29(1):95\u2013103.","journal-title":"Int J Oncol"},{"issue":"3","key":"13_CR001358","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1182\/blood-2007-07-099366","volume":"111","author":"M Schmitt","year":"2008","unstructured":"Schmitt M, et al. RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. Blood. 2008;111(3):1357\u201365.","journal-title":"Blood"},{"issue":"26","key":"13_CR001359","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian E, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349(26):2483\u201394.","journal-title":"N Engl J Med"},{"issue":"5","key":"13_CR001360","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","volume":"109","author":"S Yaccoby","year":"2007","unstructured":"Yaccoby S, et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood. 2007;109(5):2106\u201311.","journal-title":"Blood"},{"issue":"5","key":"13_CR001361","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1182\/blood-2007-03-082529","volume":"110","author":"J Qian","year":"2007","unstructured":"Qian J, et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood. 2007;110(5):1587\u201394.","journal-title":"Blood"},{"issue":"3","key":"13_CR001362","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1158\/1078-0432.CCR-06-1722","volume":"13","author":"M Grube","year":"2007","unstructured":"Grube M, et al. CD8+ T cells reactive to survivin antigen in patients with multiple myeloma. Clin Cancer Res. 2007;13(3):1053\u201360.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"13_CR001363","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1182\/blood-2002-08-2554","volume":"102","author":"SM Schmidt","year":"2003","unstructured":"Schmidt SM, et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood. 2003;102(2):571\u20136.","journal-title":"Blood"},{"issue":"6","key":"13_CR001364","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood.V84.6.1922.1922","volume":"84","author":"T Goto","year":"1994","unstructured":"Goto T, et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood. 1994;84(6):1922\u201330.","journal-title":"Blood"},{"issue":"4","key":"13_CR001365","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.exphem.2006.01.008","volume":"34","author":"M Hundemer","year":"2006","unstructured":"Hundemer M, et al. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp Hematol. 2006;34(4):486\u201396.","journal-title":"Exp Hematol"},{"issue":"6","key":"13_CR001366","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/CJI.0b013e3181a95198","volume":"32","author":"O Christensen","year":"2009","unstructured":"Christensen O, et al. Melan-A\/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24. J Immunother. 2009;32(6):613\u201321.","journal-title":"J Immunother"},{"issue":"4","key":"13_CR001367","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1158\/1078-0432.CCR-08-0989","volume":"15","author":"D Atanackovic","year":"2009","unstructured":"Atanackovic D, et al. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res. 2009;15(4):1343\u201352.","journal-title":"Clin Cancer Res"},{"key":"13_CR001368","first-page":"2","volume":"8","author":"VC Andrade","year":"2008","unstructured":"Andrade VC, et al. Prognostic impact of cancer\/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun. 2008;8:2.","journal-title":"Cancer Immun"},{"issue":"9","key":"13_CR001369","first-page":"989","volume":"87","author":"PA Ruffini","year":"2002","unstructured":"Ruffini PA, et al. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica. 2002;87(9):989\u20131001.","journal-title":"Haematologica"},{"issue":"6","key":"13_CR001370","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1073\/pnas.69.6.1540","volume":"69","author":"RG Lynch","year":"1972","unstructured":"Lynch RG, et al. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci U S A. 1972;69(6):1540\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"13_CR001371","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.ejca.2006.03.008","volume":"42","author":"L Houet","year":"2006","unstructured":"Houet L, Veelken H. Active immunotherapy of multiple myeloma. Eur J Cancer. 2006;42(11):1653\u201360.","journal-title":"Eur J Cancer"},{"issue":"10","key":"13_CR001372","first-page":"1139","volume":"88","author":"VL Reichardt","year":"2003","unstructured":"Reichardt VL, et al. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematologica. 2003;88(10):1139\u201349.","journal-title":"Haematologica"},{"issue":"11","key":"13_CR001373","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1182\/blood-2002-06-1925","volume":"101","author":"T Rasmussen","year":"2003","unstructured":"Rasmussen T, et al. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood. 2003;101(11):4607\u201310.","journal-title":"Blood"},{"issue":"1","key":"13_CR001374","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/sj.leu.2403181","volume":"18","author":"M Coscia","year":"2004","unstructured":"Coscia M, et al. Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy. Leukemia. 2004;18(1):139\u201345.","journal-title":"Leukemia"},{"issue":"1","key":"13_CR001375","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/10428190500272473","volume":"47","author":"M Bendandi","year":"2006","unstructured":"Bendandi M, et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk Lymphoma. 2006;47(1):29\u201337.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"13_CR001376","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.10095","volume":"92","author":"AO Abdalla","year":"2007","unstructured":"Abdalla AO, et al. Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma\u2014evaluation of T-cell responses by different read-out systems. Haematologica. 2007;92(1):110\u20134.","journal-title":"Haematologica"},{"issue":"5","key":"13_CR001377","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1600-0609.2007.00962.x","volume":"79","author":"AO Abdalla","year":"2007","unstructured":"Abdalla AO, et al. Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients. Eur J Haematol. 2007;79(5):371\u201381.","journal-title":"Eur J Haematol"},{"issue":"5","key":"13_CR001378","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1158\/1078-0432.CCR-06-1603","volume":"13","author":"L Hansson","year":"2007","unstructured":"Hansson L, et al. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin Cancer Res. 2007;13(5):1503\u201310.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"13_CR001379","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2141.2007.06832.x","volume":"139","author":"A Curti","year":"2007","unstructured":"Curti A, et al. Phase I\/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br J Haematol. 2007;139(3):415\u201324.","journal-title":"Br J Haematol"},{"issue":"6","key":"13_CR001380","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/annonc\/mdn017","volume":"19","author":"AO Abdalla","year":"2008","unstructured":"Abdalla AO, et al. Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC). Ann Oncol. 2008;19(6):1172\u20139.","journal-title":"Ann Oncol"},{"issue":"12","key":"13_CR001381","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/ajh.21560","volume":"84","author":"MQ Lacy","year":"2009","unstructured":"Lacy MQ, et al. Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am J Hematol. 2009;84(12):799\u2013802.","journal-title":"Am J Hematol"},{"issue":"5","key":"13_CR001382","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1365-2141.2010.08286.x","volume":"150","author":"Q Yi","year":"2010","unstructured":"Yi Q, et al. Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients. Br J Haematol. 2010;150(5):554\u201364.","journal-title":"Br J Haematol"},{"issue":"1","key":"13_CR001383","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/CJI.0b013e3181facf48","volume":"34","author":"C Rollig","year":"2011","unstructured":"Rollig C, et al. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells. J Immunother. 2011;34(1):100\u20136.","journal-title":"J Immunother"},{"issue":"3","key":"13_CR001384","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.beha.2008.07.007","volume":"21","author":"J Rosenblatt","year":"2008","unstructured":"Rosenblatt J, Avigan D. Cellular immunotherapy for multiple myeloma. Best Pract Res Clin Haematol. 2008;21(3):559\u201377.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"9","key":"13_CR001385","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.3324\/haematol.2011.056747","volume":"97","author":"TK Garg","year":"2012","unstructured":"Garg TK, et al. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica. 2012;97(9):1348\u201356.","journal-title":"Haematologica"},{"issue":"7","key":"13_CR001386","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1517\/14712598.2011.573476","volume":"11","author":"CA Ramos","year":"2011","unstructured":"Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther. 2011;11(7):855\u201373.","journal-title":"Expert Opin Biol Ther"},{"issue":"127","key":"13_CR001387","doi-asserted-by":"crossref","first-page":"127ps8","DOI":"10.1126\/scitranslmed.3003634","volume":"4","author":"SA Rosenberg","year":"2012","unstructured":"Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci Transl Med. 2012;4(127):127ps8.","journal-title":"Sci Transl Med"},{"issue":"2","key":"13_CR001388","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.coi.2009.02.009","volume":"21","author":"M Sadelain","year":"2009","unstructured":"Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21(2):215\u201323.","journal-title":"Curr Opin Immunol"},{"issue":"11","key":"13_CR001389","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1517\/14712590903260785","volume":"9","author":"BG Till","year":"2009","unstructured":"Till BG, Press OW. Treatment of lymphoma with adoptively transferred T cells. Expert Opin Biol Ther. 2009;9(11):1407\u201325.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"13_CR001390","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3324\/haematol.10873","volume":"92","author":"E Biagi","year":"2007","unstructured":"Biagi E, et al. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies. Haematologica. 2007;92(3):381\u20138.","journal-title":"Haematologica"},{"issue":"18","key":"13_CR001391","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"A Di Stasi","year":"2011","unstructured":"Di Stasi A, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673\u201383.","journal-title":"N Engl J Med"},{"issue":"6","key":"13_CR001392","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.1995.13.6.1312","volume":"13","author":"G Gahrton","year":"1995","unstructured":"Gahrton G, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol. 1995;13(6):1312\u201322.","journal-title":"J Clin Oncol"},{"issue":"2","key":"13_CR001393","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12032-007-9004-4","volume":"25","author":"A Saitoh","year":"2008","unstructured":"Saitoh A, et al. Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma. Med Oncol. 2008;25(2):137\u201347.","journal-title":"Med Oncol"},{"issue":"5","key":"13_CR001394","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/gt.2010.174","volume":"18","author":"A Barber","year":"2011","unstructured":"Barber A, Meehan KR, Sentman CL. Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells. Gene Ther. 2011;18(5):509\u201316.","journal-title":"Gene Ther"},{"key":"13_CR001395","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bbmt.2012.08.018","volume":"19","author":"KR Meehan","year":"2012","unstructured":"Meehan KR, et al. Adoptive cellular therapy using cells enriched for NKG2D(+)CD3(+)CD8(+)T cells after autologous transplantation for myeloma. Biol Blood Marrow Transplant. 2012;19:129\u201337.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"13_CR001396","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1445-5994.2009.02024.x","volume":"39","author":"S Patil","year":"2009","unstructured":"Patil S, Schwarer T. Natural killer cells\u2014new understanding of basic biology may lead to more effective allogeneic haematopoietic stem cell transplantation. Intern Med J. 2009;39(10):639\u201347.","journal-title":"Intern Med J"},{"issue":"5","key":"13_CR001397","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2141.2008.07340.x","volume":"143","author":"J Shi","year":"2008","unstructured":"Shi J, et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol. 2008;143(5):641\u201353.","journal-title":"Br J Haematol"},{"issue":"12","key":"13_CR001398","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1002\/ajh.22163","volume":"86","author":"E Katodritou","year":"2011","unstructured":"Katodritou E, et al. Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells. Am J Hematol. 2011;86(12):967\u201373.","journal-title":"Am J Hematol"},{"issue":"9","key":"13_CR001399","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-08-3712","volume":"69","author":"H Fujisaki","year":"2009","unstructured":"Fujisaki H, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69(9):4010\u20137.","journal-title":"Cancer Res"},{"issue":"6","key":"13_CR0013100","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14653240802301872","volume":"10","author":"S Arai","year":"2008","unstructured":"Arai S, et al. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy. 2008;10(6): 625\u201332.","journal-title":"Cytotherapy"},{"issue":"7","key":"13_CR0013101","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3324\/haematol.2011.054254","volume":"97","author":"BE Swift","year":"2012","unstructured":"Swift BE, et al. Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. Haematologica. 2012;97(7):1020\u20138.","journal-title":"Haematologica"},{"issue":"6","key":"13_CR0013102","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1182\/blood-2007-09-110312","volume":"111","author":"E Alici","year":"2008","unstructured":"Alici E, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood. 2008;111(6):3155\u201362.","journal-title":"Blood"},{"issue":"6","key":"13_CR0013103","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1084\/jem.155.6.1823","volume":"155","author":"EA Grimm","year":"1982","unstructured":"Grimm EA, et al. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155(6):1823\u201341.","journal-title":"J Exp Med"},{"issue":"1","key":"13_CR0013104","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.174.1.139","volume":"174","author":"IG Schmidt-Wolf","year":"1991","unstructured":"Schmidt-Wolf IG, et al. Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174(1):139\u201349.","journal-title":"J Exp Med"},{"key":"13_CR0013105","first-page":"435745","volume":"2010","author":"YC Linn","year":"2010","unstructured":"Linn YC, Hui KM. Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol. 2010;2010:435745.","journal-title":"J Biomed Biotechnol"},{"issue":"10","key":"13_CR0013106","first-page":"1029","volume":"86","author":"A Marten","year":"2001","unstructured":"Marten A, et al. Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica. 2001;86(10):1029\u201337.","journal-title":"Haematologica"},{"issue":"21","key":"13_CR0013107","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.2169\/internalmedicine.49.3996","volume":"49","author":"J Lin","year":"2010","unstructured":"Lin J, et al. Autologous cytokine-induced killer cells in the treatment of multiple myeloma concomitant with lung cancer and paraneoplastic dermatoses. Intern Med. 2010;49(21):2341\u20136.","journal-title":"Intern Med"},{"issue":"4","key":"13_CR0013108","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.mt.6300108","volume":"15","author":"E Kelly","year":"2007","unstructured":"Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther. 2007;15(4):651\u20139.","journal-title":"Mol Ther"},{"issue":"7","key":"13_CR0013109","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658\u201370.","journal-title":"Nat Biotechnol"},{"issue":"4","key":"13_CR0013110","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/14712598.8.4.463","volume":"8","author":"AE Stief","year":"2008","unstructured":"Stief AE, McCart JA. Oncolytic virotherapy for multiple myeloma. Expert Opin Biol Ther. 2008;8(4): 463\u201373.","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"13_CR0013111","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2012.70","volume":"26","author":"S Naik","year":"2012","unstructured":"Naik S, et al. Curative one-shot systemic virotherapy in murine myeloma. Leukemia. 2012;26(8):1870\u20138.","journal-title":"Leukemia"},{"key":"13_CR0013112","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1158\/1078-0432.CCR-11-3085","volume":"18","author":"CM Thirukkumaran","year":"2012","unstructured":"Thirukkumaran CM, et al. Reovirus as a viable therapeutic option for the treatment of multiple myeloma. Clin Cancer Res. 2012;18:4962\u201372.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"13_CR0013113","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/cgt.2012.14","volume":"19","author":"S Naik","year":"2012","unstructured":"Naik S, et al. Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-beta. Cancer Gene Ther. 2012;19(7):443\u201350.","journal-title":"Cancer Gene Ther"},{"issue":"10","key":"13_CR0013114","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.bbmt.2012.04.004","volume":"18","author":"E Bartee","year":"2012","unstructured":"Bartee E, et al. Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus. Biol Blood Marrow Transplant. 2012;18(10):1540\u201351.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"13_CR0013115","doi-asserted-by":"crossref","first-page":"6712","DOI":"10.1158\/1078-0432.CCR-11-0968","volume":"17","author":"CY Chen","year":"2011","unstructured":"Chen CY, et al. Species D adenoviruses as oncolytics against B-cell cancers. Clin Cancer Res. 2011;17(21): 6712\u201322.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"13_CR0013116","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1038\/mt.2011.68","volume":"19","author":"EM Hadac","year":"2011","unstructured":"Hadac EM, Kelly EJ, Russell SJ. Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid. Mol Ther. 2011;19(6):1041\u20137.","journal-title":"Mol Ther"},{"issue":"12","key":"13_CR0013117","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1038\/leu.2008.120","volume":"22","author":"H Deng","year":"2008","unstructured":"Deng H, et al. Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus. Leukemia. 2008;22(12):2261\u20134.","journal-title":"Leukemia"},{"issue":"5","key":"13_CR0013118","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1182\/blood-2003-07-2233","volume":"103","author":"D Dingli","year":"2004","unstructured":"Dingli D, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood. 2004;103(5):1641\u20136.","journal-title":"Blood"},{"issue":"1","key":"13_CR0013119","first-page":"79","volume":"57","author":"A Kawa","year":"1987","unstructured":"Kawa A, Arakawa S. The effect of attenuated vaccinia virus AS strain on multiple myeloma; a case report. Jpn J Exp Med. 1987;57(1):79\u201381.","journal-title":"Jpn J Exp Med"},{"issue":"10","key":"13_CR0013120","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/gt.2008.45","volume":"15","author":"A Munguia","year":"2008","unstructured":"Munguia A, et al. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther. 2008;15(10):797\u2013806.","journal-title":"Gene Ther"},{"key":"13_CR0013121","doi-asserted-by":"crossref","first-page":"632948","DOI":"10.1155\/2011\/632948","volume":"2011","author":"CM Thirukkumaran","year":"2011","unstructured":"Thirukkumaran CM, Morris DG. Oncolytic virotherapy for multiple myeloma: past, present, and future. Bone Marrow Res. 2011;2011:632948.","journal-title":"Bone Marrow Res"},{"issue":"2","key":"13_CR0013122","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","volume":"73","author":"TJ Wickham","year":"1993","unstructured":"Wickham TJ, et al. Integrins \u00b1v23 and \u00b1v25 promote adenovirus internalization but not virus attachment. Cell. 1993;73(2):309\u201319.","journal-title":"Cell"},{"issue":"12","key":"13_CR0013123","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1182\/blood.V92.12.4591","volume":"92","author":"G Teoh","year":"1998","unstructured":"Teoh G, et al. Adenovirus vector-based purging of multiple myeloma cells. Blood. 1998;92(12):4591\u2013601.","journal-title":"Blood"},{"issue":"1","key":"13_CR0013124","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood.V81.1.128.128","volume":"81","author":"A Neri","year":"1993","unstructured":"Neri A, et al. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood. 1993;81(1):128\u201335.","journal-title":"Blood"},{"issue":"12","key":"13_CR0013125","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/S0301-472X(00)00556-7","volume":"28","author":"Q Liu","year":"2000","unstructured":"Liu Q, Gazitt Y. Adenovirus-mediated delivery of p53 results in substantial apoptosis to myeloma cells and is not cytotoxic to flow-sorted CD34(+) hematopoietic progenitor cells and normal lymphocytes. Exp Hematol. 2000;28(12):1354\u201362.","journal-title":"Exp Hematol"},{"issue":"5","key":"13_CR0013126","first-page":"1434","volume":"60","author":"T Otsuki","year":"2000","unstructured":"Otsuki T, et al. Estrogen receptors in human myeloma cells. Cancer Res. 2000;60(5):1434\u201341.","journal-title":"Cancer Res"},{"issue":"3","key":"13_CR0013127","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1046\/j.1365-2141.2001.02499.x","volume":"112","author":"CS Wilson","year":"2001","unstructured":"Wilson CS, et al. Cyclin D1 and E2F-1 immunoreactivity in bone marrow biopsy specimens of multiple myeloma: relationship to proliferative activity, cytogenetic abnormalities and DNA ploidy. Br J Haematol. 2001;112(3):776\u201382.","journal-title":"Br J Haematol"},{"issue":"15","key":"13_CR0013128","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1158\/1078-0432.CCR-09-0451","volume":"15","author":"MS Fernandes","year":"2009","unstructured":"Fernandes MS, et al. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene. Clin Cancer Res. 2009;15(15):4847\u201356.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"13_CR0013129","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1089\/hum.2009.082","volume":"21","author":"JS Senac","year":"2010","unstructured":"Senac JS, et al. Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther. 2010;21(2):179\u201390.","journal-title":"Hum Gene Ther"},{"issue":"6","key":"13_CR0013130","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1128\/jvi.71.6.4736-4743.1997","volume":"71","author":"DR Shafren","year":"1997","unstructured":"Shafren DR, et al. Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry. J Virol. 1997;71(6):4736\u201343.","journal-title":"J Virol"},{"issue":"2","key":"13_CR0013131","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2141.2007.06550.x","volume":"137","author":"GG Au","year":"2007","unstructured":"Au GG, et al. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol. 2007;137(2):133\u201341.","journal-title":"Br J Haematol"},{"issue":"11","key":"13_CR0013132","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/nm.1776","volume":"14","author":"EJ Kelly","year":"2008","unstructured":"Kelly EJ, et al. Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med. 2008;14(11):1278\u201383.","journal-title":"Nat Med"},{"issue":"10","key":"13_CR0013133","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1128\/jvi.67.10.6025-6032.1993","volume":"67","author":"D Naniche","year":"1993","unstructured":"Naniche D, et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol. 1993;67(10):6025\u201332.","journal-title":"J Virol"},{"issue":"6798","key":"13_CR0013134","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/35022579","volume":"406","author":"H Tatsuo","year":"2000","unstructured":"Tatsuo H, et al. SLAM (CDw150) is a cellular receptor for measles virus. Nature. 2000;406(6798):893\u20137.","journal-title":"Nature"},{"issue":"6","key":"13_CR0013135","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.exphem.2006.03.002","volume":"34","author":"HT Ong","year":"2006","unstructured":"Ong HT, et al. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol. 2006;34(6):713\u201320.","journal-title":"Exp Hematol"},{"issue":"1","key":"13_CR0013136","first-page":"43","volume":"11","author":"P Msaouel","year":"2009","unstructured":"Msaouel P, Dispenzieri A, Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther. 2009;11(1):43\u201353.","journal-title":"Curr Opin Mol Ther"},{"issue":"7","key":"13_CR0013137","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1182\/blood.V98.7.2002","volume":"98","author":"KW Peng","year":"2001","unstructured":"Peng KW, et al. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood. 2001;98(7):2002\u20137.","journal-title":"Blood"},{"issue":"6","key":"13_CR0013138","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/mt.2010.43","volume":"18","author":"C Liu","year":"2010","unstructured":"Liu C, Russell SJ, Peng KW. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers. Mol Ther. 2010;18(6):1155\u201364.","journal-title":"Mol Ther"},{"issue":"7","key":"13_CR0013139","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.21444","volume":"84","author":"KW Peng","year":"2009","unstructured":"Peng KW, et al. Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Am J Hematol. 2009;84(7):401\u20137.","journal-title":"Am J Hematol"},{"issue":"4","key":"13_CR0013140","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/sj.gt.3302880","volume":"14","author":"HT Ong","year":"2007","unstructured":"Ong HT, et al. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther. 2007;14(4):324\u201333.","journal-title":"Gene Ther"},{"issue":"6","key":"13_CR0013141","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/sj.clpt.6100409","volume":"82","author":"RM Myers","year":"2007","unstructured":"Myers RM, et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther. 2007;82(6):700\u201310.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"13_CR0013142","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/jnci\/93.12.903","volume":"93","author":"ME Wilcox","year":"2001","unstructured":"Wilcox ME, et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst. 2001;93(12):903\u201312.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"13_CR0013143","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1158\/0008-5472.CAN-09-2408","volume":"70","author":"CM Thirukkumaran","year":"2010","unstructured":"Thirukkumaran CM, et al. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res. 2010;70(6):2435\u201344.","journal-title":"Cancer Res"},{"issue":"5","key":"13_CR0013144","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1089\/10430340252837233","volume":"13","author":"KL Norman","year":"2002","unstructured":"Norman KL, et al. Reovirus oncolysis of human breast cancer. Hum Gene Ther. 2002;13(5):641\u201352.","journal-title":"Hum Gene Ther"},{"issue":"7","key":"13_CR0013145","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.clon.2008.04.018","volume":"20","author":"C Comins","year":"2008","unstructured":"Comins C, et al. Reovirus: viral therapy for cancer \u2018as nature intended\u2019. Clin Oncol. 2008;20(7):548\u201354.","journal-title":"Clin Oncol"},{"issue":"6","key":"13_CR0013146","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1182\/blood-2010-05-284422","volume":"117","author":"T Steinbrunn","year":"2011","unstructured":"Steinbrunn T, et al. Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. Blood. 2011;117(6):1998\u20132004.","journal-title":"Blood"},{"issue":"1","key":"13_CR0013147","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood-2002-08-2508","volume":"102","author":"CM Thirukkumaran","year":"2003","unstructured":"Thirukkumaran CM, et al. Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation. Blood. 2003;102(1):377\u201387.","journal-title":"Blood"},{"issue":"25","key":"13_CR0013148","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1038\/onc.2011.478","volume":"31","author":"KR Kelly","year":"2012","unstructured":"Kelly KR, et al. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene. 2012;31(25):3023\u201338.","journal-title":"Oncogene"},{"issue":"21","key":"13_CR0013149","doi-asserted-by":"crossref","first-page":"7127","DOI":"10.1158\/1078-0432.CCR-08-0524","volume":"14","author":"L Vidal","year":"2008","unstructured":"Vidal L, et al. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res. 2008;14(21): 7127\u201337.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"13_CR0013150","first-page":"154","volume":"27","author":"EB Gurvich","year":"1983","unstructured":"Gurvich EB, Vilesova IS. Vaccinia virus in postvaccinal encephalitis. Acta Virol. 1983;27(2):154\u20139.","journal-title":"Acta Virol"},{"issue":"1","key":"13_CR0013151","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/1097-0142(197707)40:1<226::AID-CNCR2820400135>3.0.CO;2-1","volume":"40","author":"SB Turkel","year":"1977","unstructured":"Turkel SB, Overturf GD. Vaccinia necrosum complicating immunoblastic sarcoma. Cancer. 1977;40(1):226\u201333.","journal-title":"Cancer"},{"issue":"9","key":"13_CR0013152","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1089\/hum.2004.15.821","volume":"15","author":"BD Lichty","year":"2004","unstructured":"Lichty BD, et al. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther. 2004;15(9): 821\u201331.","journal-title":"Hum Gene Ther"},{"issue":"7","key":"13_CR0013153","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1182\/blood-2007-01-065573","volume":"110","author":"A Goel","year":"2007","unstructured":"Goel A, et al. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood. 2007;110(7):2342\u201350.","journal-title":"Blood"}],"container-title":["Multiple Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4614-8520-9_13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T02:53:44Z","timestamp":1676343224000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-4614-8520-9_13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,4]]},"ISBN":["9781461485193","9781461485209"],"references-count":153,"URL":"https:\/\/doi.org\/10.1007\/978-1-4614-8520-9_13","relation":{},"subject":[],"published":{"date-parts":[[2013,9,4]]},"assertion":[{"value":"4 September 2013","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}